RayBiotech, Inc. and the combined genotyping core facility for Oslo University Hospital and the University of Oslo, located at the Institute for Cancer Research, announced the execution of an agreement to collaborate for the implementation of antibody-based sample analysis services. Under the terms of the agreement, the combined core facility will provide a comprehensive service utilizing RayBiotech's proprietary antibody arrays for the high-throughput detection and analysis of protein biomarkers in biological samples. The service program will target academic and industrial research clients having a need for fully quantifiable biomarker analysis.
RayBiotech's Quantibody® array platform, which delivers high throughput quantitative expression profiles, will be a key component of the core facility's service program. Potential biomarkers will include cytokines, growth factors, and other secreted factors related to cancer and other complex diseases. The service will be applicable to both human specimens and animal models such as mice, rats, pigs, and primates.
RayBiotech will work closely with the Institute for Cancer Research, the Oslo University Hospital and the University of Oslo to provide all the necessary products, technical expertise, and marketing and sales support needed to implement the services program. Financial terms were not disclosed.